Literature DB >> 22156790

Secondary erythromelalgia successfully treated with intravenous immunoglobulin.

Shadé Moody1, Susan Pacheco, Ian J Butler, Mary Kay Koenig.   

Abstract

Erythromelalgia is a rare condition characterized by episodic painful erythema and warmth often affecting, but not limited to, the distal extremities. This condition is notoriously difficult to treat. We report a young female patient with seronegative polyarthritis who presented with a 6-year history of recurrent bouts of painful erythema and swelling often triggered by minor trauma. An extensive evaluation was unremarkable. Several medical therapies provided limited and inconsistent relief of her symptoms over many years. Treatment with intravenous immunoglobulin significantly decreased the frequency and severity of her symptoms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22156790     DOI: 10.1177/0883073811427784

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  4 in total

1.  Successful treatment of adult-onset erythromelalgia with steroid pulse and pregabalin.

Authors:  Aya Kakizaki; Taku Fujimura; Yumi Kambayashi; Akiko Watabe; Setsuya Aiba
Journal:  Case Rep Dermatol       Date:  2012-09-13

2.  An Egyptian child with erythromelalgia responding to a new line of treatment: a case report and review of the literature.

Authors:  Samir M Al-Minshawy; Abdel-Azeem M El-Mazary
Journal:  J Med Case Rep       Date:  2014-02-25

3.  Intravenous immunoglobulin therapy for small fiber neuropathy: study protocol for a randomized controlled trial.

Authors:  Bianca T A de Greef; Margot Geerts; Janneke G J Hoeijmakers; Catharina G Faber; Ingemar S J Merkies
Journal:  Trials       Date:  2016-07-20       Impact factor: 2.279

Review 4.  Current pain management strategies for patients with erythromelalgia: a critical review.

Authors:  See Wan Tham; Marian Giles
Journal:  J Pain Res       Date:  2018-08-30       Impact factor: 3.133

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.